when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Oct 1, 26M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buybiospace

Oct 1, 26Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor datafiercebiotech

Oct 1, 26The top 12 companies hiring in biopharma nowbiospace

Sep 30, 26Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3biospace

Sep 30, 26STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trialstat

Sep 30, 26Lilly builds commercial case for GLP-1 products over Novo with indirect analysesbiospace

Sep 30, 26Lilly raises diabetes weight-loss bar with amylin-Zepbound combofiercebiotech

Sep 30, 26AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a rollbiospace

Sep 30, 26Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal programfiercebiotech

Sep 30, 26Trend of women-led M&A fades in 2026 with just two deals so farbiospace

Sep 30, 26Lilly sets up next-gen obesity battle with full phase 3 retatrutide datafiercebiotech

Sep 29, 26#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity thresholdendpoints

Sep 29, 26Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillbiopharma dive

Sep 29, 26Roche cuts muscle-sparing obesity drug after mid-stage disappointmentbiospace

Sep 29, 26STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and morestat

Sep 29, 26Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengruifiercebiotech

Sep 28, 26‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futurefiercebiotech

Sep 28, 26STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and morestat

Sep 28, 26STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’stat

Sep 28, 266 immunology targets to sustain a mammoth I&I marketbiospace

Sep 25, 26Jury awards Nektar $90M in suit against Lillyendpoints

Sep 25, 26This week in charts: Novo’s rise and fall and AI biotechs’ big haulbiopharma dive

Sep 25, 26STAT+: Lilly wins approval for once-weekly insulin shotstat

Sep 25, 26Nektar prevails in legal battle with Lilly over broken rezpeg partnershipbiospace

Sep 25, 26Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugsendpoints

Sep 25, 26Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapyendpoints

Sep 25, 26STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morestat

Sep 25, 26Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s databiopharma dive

Sep 25, 26Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectablesfiercebiotech

Sep 24, 26FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’biospace

← prevpage 5 of 21next →